Table 1 Summary of drug therapies
Target | Agent | Most common adverse events reported to FDA | Relevant protocol(s) | Pharmaceutical source |
|---|---|---|---|---|
Heterodimerization of HER2 with HER3 receptor | Pertuzumab | Diarrhea, alopecia, neutropenia, nausea, fatigue, rash, peripheral neuropathy, infusion and hypersensitivity reactions | CLEOPATRA (NCT00567190) NCT01358877 | Roche-Genentech |
| Â | Â | Â | VELVET (NCT01565083) | |
| Â | Â | Â | PERTAIN (NCT01491737) | |
| Â | Â | Â | PERUSE (NCT01572038) | |
HER2 receptor | Trastuzumab-maytansine [DM1] | Fatigue, nausea, thrombocytopenia, cellulitis, elevated liver enzymes, left ventricular dysfunction, neurotoxicity | EMILIA (NCT00829166) | Roche-Genentech |
| Â | Â | Â | MARIANNE (NCT01120184) | |
Multi-targeted receptor tyrosine kinase inhibitor | Pazopanib | Diarrhea, change in hair color, nausea, vomiting, loss of appetite, fatigue, liver dysfunction | VEG108838 (NCT00558103) | GlaxoSmithKline |
| Â | Â | Â | NSABP (FB-6) (NCT00849472) | |
Irreversible binder of the HER receptors [HER1, HER2, and HER3] | Afatinib | Safety and efficacy not fully established by the FDA. | Boehringer Ingelheim | |
| Â | Â | Likely gastrointestinal and skin-related side effects from HER 1 blockade | LUX-Breast 1 (NCT01125566) | |
| Â | Â | Â | LUX-breast 2 (NCT01271725) | |
| Â | Â | Â | LUX-breast 3 (NCT01441596) | |
| Â | Â | Â | ||
Irreversible binder of the HER receptors [HER1, HER2, and HER3] | Neratinib | Safety and efficacy not fully established by the FDA. | ExteNet (NCT00878709) | Puma Biotechnology |
| Â | Â | Â | NSABP (FB-8) (NCT01423123) NCT01494662 | |
| Â | Â | Â | NSABP FB-7 (NCT01008150) |